Projects per year
Our group investigates the primary brain tumour glioblastoma (GBM), one of the most aggressive and incurable tumours in adults. Treatment comprises surgery, radiation, and chemotherapy (temozolomide). Even with this aggressive therapy, tumours inevitably recur, conferring a life expectancy of approximately one year. Intensive research using conventional preclinical models, such as cells are grown in two-dimensional conditions (plastic dishes) or in three-dimensional models devoid of extracellular matrix or scaffolding support such as neurospheres, have identified multiple molecular targeted agents which have all failed in the clinic. Failure in the clinical translation of these agents imply that the conventional preclinical models used are not representative of GBM or its response to treatment. To elicit improved therapies for GBM patients and improve the poor survival rates, research in our group has focused in the development of appropriate models that better recapitulate the GBM microenvironment and evaluate how these cells respond to treatment.
Using a three-dimensional GBM model developed in our laboratory, that recapitulates key clinical features including cell morphology, migration, and clinical response to molecular targeted therapies, we have identified several molecular targets that induce radiation sensitivity as well as radiation protection. We are currently investigating the mechanisms involved in these responses, in order to identify better treatments with clinical efficacy.
- ovarian cancer
- DNA damage and repair
- 12 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
1/04/21 → 31/03/23
1/04/21 → 31/03/22
Gomez-Roman, N., Chalmers, A. J., Norman, J. C. & Tait, S. W. G., 21 Sep 2020, In: Scientific Reports. 10, 1, 10 p., 15361.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile4 Downloads (Pure)
Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJGomez-Roman, N., Chong, M. Y., Chahal, S. K., Caragher, S. P., Jackson, M. R., Stevenson, K. H., Dongre, S. A. & Chalmers, A. J., 29 Feb 2020, In: Molecular Cancer Therapeutics. 19, 2, p. 575-589 15 p.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile